Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fareed

Showing results (231-240 of 384) with videos related to

Pageof 39
Sort By:
Current Pharmaceutical Design|April 14, 2004
Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature reviewH L Messmore, E Coyne, W H Wehrmacher, et al.
International Angiology : a Journal of the International Union of Angiology|December 17, 2008
Contaminants in heparins continue to be unfoldedJ Fareed, M Ahluwalia, R Wahi, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparinsH L Messmore, B Griffin, M Koza, et al.
Thrombosis Research|January 15, 1992
Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systemsB Kaiser, J Fareed, D Hoppensteadt, et al.
Annals of Clinical and Laboratory Science|July 1, 1978
Macroglobulinemia of Waldenström diagnosis and managementH L Messmore, J Fareed, S Silberman, et al.
Thrombosis Research|May 15, 1993
A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate modelP Bacher, O Iqbal, B Lojewski, et al.
Journal of Thrombosis and Haemostasis : JTH|April 26, 2013
Update of the recommendations on biosimilar low-molecular-weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and HaemostasisJ Harenberg, J Walenga, G Torri, et al.
Thrombosis Research|April 1, 1997
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharideJ M Walenga, W P Jeske, L Bara, et al.
Thrombosis Research|December 12, 2001
Singlet oxygen (1O(2)) disrupts platelet aggregatesT W Stief, U Feek, A Ramaswamy, et al.
Journal of Pharmaceutical Sciences|June 1, 1995
Molecular profiling and weight determination of heparins and depolymerized heparinsA Ahsan, W Jeske, D Hoppensteadt, et al.
Pageof 39

Showing results (231-240 of 384) with videos related to

Sort By:
Pageof 39
Current Pharmaceutical Design|April 14, 2004
Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature reviewH L Messmore, E Coyne, W H Wehrmacher, et al.
International Angiology : a Journal of the International Union of Angiology|December 17, 2008
Contaminants in heparins continue to be unfoldedJ Fareed, M Ahluwalia, R Wahi, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparinsH L Messmore, B Griffin, M Koza, et al.
Thrombosis Research|January 15, 1992
Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systemsB Kaiser, J Fareed, D Hoppensteadt, et al.
Annals of Clinical and Laboratory Science|July 1, 1978
Macroglobulinemia of Waldenström diagnosis and managementH L Messmore, J Fareed, S Silberman, et al.
Thrombosis Research|May 15, 1993
A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate modelP Bacher, O Iqbal, B Lojewski, et al.
Journal of Thrombosis and Haemostasis : JTH|April 26, 2013
Update of the recommendations on biosimilar low-molecular-weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and HaemostasisJ Harenberg, J Walenga, G Torri, et al.
Thrombosis Research|April 1, 1997
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharideJ M Walenga, W P Jeske, L Bara, et al.
Thrombosis Research|December 12, 2001
Singlet oxygen (1O(2)) disrupts platelet aggregatesT W Stief, U Feek, A Ramaswamy, et al.
Journal of Pharmaceutical Sciences|June 1, 1995
Molecular profiling and weight determination of heparins and depolymerized heparinsA Ahsan, W Jeske, D Hoppensteadt, et al.
Pageof 39